NCT06922604View on ClinicalTrials.gov

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 23, 2025

Primary Completion Date

January 2, 2029

Study Completion Date

January 2, 2029

Conditions
Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo CSF and blood sample collection

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

BIOLOGICAL

Glofitamab

Given IV

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Magnetic Resonance Imaging

Undergo brain MRI

BIOLOGICAL

Obinutuzumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT06922604 - Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma | Biotech Hunter | Biotech Hunter